{
    "clinical_study": {
        "@rank": "1560", 
        "arm_group": {
            "arm_group_label": "patient receiving one PDT session", 
            "arm_group_type": "Experimental", 
            "description": "patient receiving one photodynamic therapy (PDT) session"
        }, 
        "brief_summary": {
            "textblock": "The hereditary dystrophic epidermolysis bullosa are genodermatosis responsible of a poor\n      adhesion of the epidermis to the dermis pulling a large mucocutaneous fragility and\n      recurrent spontaneous or posttraumatic bullous detachment. They are caused by mutations in\n      the COL7A1 gene encoding for the collagen VII.\n\n      No curative treatment is avaible. The main cause of patients death is the development of\n      squamous cell carcinoma, sometimes multiple and paticularly aggressive in repeated healing\n      part. The photodynamic therapy (PDT) is one of technical reference of multiple actinic\n      keratoses lesions for adults, which are also pre-epithelioma lesions. The PDT is well\n      tolerated even by the elderly and requires only a single session.\n\n      The main objective of this study is to determine the efficiency of the photodynamic therapy\n      in the treatment of epidermic dysplasies for patients affected by dystrophic epidermolysis\n      bullosa (DEB). The secondary objectives are to evaluate the tolerance of this treatment in\n      terms of pain and healing, and to evaluate the contribution of confocal microscopy in the\n      diagnosis of epidermal dysplasia for patients affected by hereditary dystrophic\n      epidermolysis bullosa. The main evaluation criterion is the cutaneous biopsy before and\n      after (M2) a PDT session of an epidermal dysplasia area. The secondary criteria are the\n      evaluation of the pain during the PDT session and the healing of the cutaneous lesion at M0,\n      M2 and M4 (lesion area and healing time) and correlation histology / MC.  Each patient with\n      a suspicious lesion will be biopsied. In case of agreement for this protocol, there will be\n      1 PDT session followed by a consultation of control at 2 and 4 months after the end of\n      treatment."
        }, 
        "brief_title": "Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Dystrophic Epidermolysis Bullosa", 
        "condition_browse": {
            "mesh_term": [
                "Epidermolysis Bullosa", 
                "Epidermolysis Bullosa Dystrophica"
            ]
        }, 
        "detailed_description": {
            "textblock": "The hereditary dystrophic epidermolysis bullosa are genodermatosis responsible of a poor\n      adhesion of the epidermis to the dermis pulling a large mucocutaneous fragility and\n      recurrent spontaneous or posttraumatic bullous detachment. They are caused by mutations in\n      the COL7A1 gene encoding for the collagen VII.\n\n      No curative treatment is avaible. The main cause of patients death is the development of\n      squamous cell carcinoma, sometimes multiple and paticularly aggressive in repeated healing\n      part. The early treatment of pre-epithelioma cutaneous lesions to moderate at severe\n      dysplasia type would undoubtedly allow to improve the prognosis of patients. Because of the\n      cutaneous fragility of patients, topical treatments such as imiquimod or 5-FU are not\n      possible. The photodynamic therapy (PDT) is one of technical reference of multiple actinic\n      keratoses lesions for adults, which are also pre-epithelioma lesions. The PDT is well\n      tolerated even by the elderly and requires only a single session.\n\n      The main objective of this study is to determine the efficiency of the photodynamic therapy\n      in the treatment of epidermic dysplasies for patients affected by dystrophic epidermolysis\n      bullosa (DEB). The secondary objectives are to evaluate the tolerance of this treatment in\n      terms of pain and healing, and to evaluate the contribution of confocal microscopy in the\n      diagnosis of epidermal dysplasia for patients affected by hereditary dystrophic\n      epidermolysis bullosa. The main evaluation criterion is the cutaneous biopsy before and\n      after (M2) a PDT session of an epidermal dysplasia area. The secondary criteria are the\n      evaluation of the pain during the PDT session and the healing of the cutaneous lesion at M0,\n      M2 and M4 (lesion area and healing time) and correlation histology / MC. This is a\n      bicentric, open and pilot study on 5 patients over 18 years affected by hereditary\n      dystrophic epidermolysis bullosa with epidermal displasia. Carcinomas in situ were excluded\n      of this study. Each patient with a suspicious lesion will be biopsied. In case of agreement\n      for this protocol, there will be 1 PDT session followed by a consultation of control at 2\n      and 4 months after the end of treatment.\n\n      Total study duration: 18 months (12 months for inclusions, 4 months for study, 2 months for\n      data analysis)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient carrying a widespread EBDR with moderate to severe epidermal dysplasia on a\n             cutaneous biopsy of a suspicious lesion. Any clinically suspicious lesion should be\n             biopsied in these patients, the inclusion will be made only after obtaining the\n             results of the histological examination.\n\n          -  The size of the lesion will be between 10 cm\u00b2 and 1cm\u00b2.\n\n          -  Systematic Obtaining of the signed informed consent\n\n          -  Patient affiliated to Social Security\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women.\n\n          -  Patients unable to cooperate for all the duration of the study.\n\n          -  Squamous cell carcinoma in situ or invasive on biopsy.\n\n          -  Patient treated by chemotherapy for another reason.\n\n          -  Contraindication at the PDT, patient unable to lie over an hour.\n\n          -  Contraindication at fentanyl ( 50mcg Instanyl ) intra nasal :\n\n        oHypersensitivity to the active substance or to any of the excipients oUse in patients who\n        have never received opioid treatment. oSevere respiratory depression or severe airway\n        obstruction. oPrevious radiotherapy of the face. oRecurrent episodes of epistaxis\n        oConcomitant administration of monoamine oxidase inhibitors, of potent CYP 3A4 inhibitors,\n        of nasal decongestants, or other drugs (other than oxymetazoline ) administered by nasal\n        way.\n\n        oSevere hepatic or renal insufficiency.\n\n        \u2022Patients who have participated in a clinical trial in the previous 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004600", 
            "org_study_id": "13-AOI-11"
        }, 
        "intervention": {
            "arm_group_label": "patient receiving one PDT session", 
            "description": "1 session of Photodynamic therapy (PDT) on epidermis dysplasia", 
            "intervention_name": "Photodynamic therapy (PDT)", 
            "intervention_type": "Procedure", 
            "other_name": "1 session of Photodynamic therapy (PDT)"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Nice", 
                        "country": "France", 
                        "zip": "06000"
                    }, 
                    "name": "Nice University Hospital"
                }, 
                "investigator": {
                    "last_name": "CHRISTINE CHIAVERINI, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France"
                    }, 
                    "name": "Saint Louis Hospital"
                }, 
                "investigator": {
                    "last_name": "Emmanuelle BOURRAT, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Bicentric, Open and Pilot Study Evaluating the Efficiency and the Tolerance of the Photodynamic Therapy in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary Dystrophic Epidermolysis Bullosa", 
        "overall_contact": {
            "email": "chiaverini.c@chu-nice.fr", 
            "last_name": "CHRISTINE CHIAVERINI, MD"
        }, 
        "overall_official": {
            "affiliation": "Nice University Hospital", 
            "last_name": "Christine CHIAVERINI, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Histological examination of a cutaneous biopsy at M2 on the epidermal dysplasia area treated with PDT session", 
            "measure": "Histological examination of a cutaneous biopsy", 
            "safety_issue": "No", 
            "time_frame": "2 MONTHS AFTER ENROLLMENT"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004600"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tolerance of PDT : evaluation of pain every 10 minutes during PDT session", 
            "measure": "Tolerance of PDT", 
            "safety_issue": "No", 
            "time_frame": "every 10 minutes during PDT session"
        }, 
        "source": "Centre Hospitalier Universitaire de Nice", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Hospitalier Universitaire de Nice", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}